Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramon Garcia-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izquierdo, Izidore S. Lossos, Craig Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, Andras Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

Blood (2020) 136 (21): 2401–2409.

https://doi.org/10.1182/blood.2019004701

Published: 2020

Includes: Supplemental data

Journal Articles

Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis

Angeline J Pallante, MD, Nelson Leung, MD, Robert A. Kyle, MD, Ayalew Tefferi, MD, Stephen J. Russell, MD PhD, Thomas M. Habermann, MD, Martha Q. Lacy, MD, Suzanne R. Hayman, MD, Aref Al-Kali, MD, Craig Reeder, MD, Angela Dispenzieri, MD, Morie A. Gertz, MD, Francis K Buadi, MD, C. Christopher Hook, MD, David Dingli, MD PhD, Animesh Pardanani, MD PhD

Blood (2016) 128 (22): 5480.

https://doi.org/10.1182/blood.V128.22.5480.5480

Published: 2016

Journal Articles

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Thomas E. Witzig, Craig Reeder, Jing Jing Han, Betsy LaPlant, Mary Stenson, Han W. Tun, William Macon, Stephen M. Ansell, Thomas M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir Markovic, Grzegorz S. Nowakowski, Mamta Gupta

Blood (2015) 126 (3): 328–335.

https://doi.org/10.1182/blood-2015-02-629543

Published: 2015

Includes: Supplemental data

Journal Articles

Smoldering multiple myeloma requiring treatment: time for a new definition?

Blood (2013) 122 (26): 4172–4181.

https://doi.org/10.1182/blood-2013-08-520890

Published: 2013

Journal Articles

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Wei Ding, MD, PhD, Tait D Shanafelt, MD, Clive S. Zent, MD, Jose F. Leis, MD, PhD, Betsy R. LaPlant, Timothy G. Call, MD, Curtis A Hanson, MD, Charles Erlichman, MD, Thomas M. Habermann, MD, Craig Reeder, MD, Daniel Nikcevich, Deborah Bowen, CNP, Michael J. Conte, PA-C, Justin Boysen, Charla Secreto, Connie Lesnick, M.Sc, Renee C. Tschumper, Diane F. Jelinek, PhD, Neil E. Kay, MD

Blood (2013) 122 (21): 2882.

https://doi.org/10.1182/blood.V122.21.2882.2882

Published: 2013

Journal Articles

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

Shaji K Kumar, MD, Vivek Roy, M.D., Craig Reeder, MD, Betsy R. LaPlant, Martha Q Lacy, MD, Morie A Gertz, MD, MACP, Kristina Laumann, Melanie Ann Thompson, Thomas E Witzig, MD, Francis K Buadi, MD, Candido E. Rivera, MD, Joseph R. Mikhael, MD, Peter Leif Bergsagel, MD, Lisa Hwa, RN, CNP, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2013) 122 (21): 1944.

https://doi.org/10.1182/blood.V122.21.1944.1944

Published: 2013

Journal Articles

A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma

Blood (2013) 122 (21): 1940.

https://doi.org/10.1182/blood.V122.21.1940.1940

Published: 2013

Journal Articles

Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs

Aneel Paulus, MD, MS, Kasyapa S. Chitta, PhD, Sharoon Akhtar, Maja Kuranz, Shaji Kumar, MD, Vivek Roy, MD, FACP, Stephen M. Ansell, M.D.Ph.D., Joseph R. Mikhael, MD, Angela Dispenzieri, MD, Craig Reeder, MD, Candido E. Rivera, MD, James M. Foran, MD, Francis Buadi, MD, Vincent Rajkumar, MD, Asher Chanan-Khan, MD

Blood (2013) 122 (21): 1928.

https://doi.org/10.1182/blood.V122.21.1928.1928

Published: 2013

Journal Articles

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

Blood (2013) 122 (21): 4352.

https://doi.org/10.1182/blood.V122.21.4352.4352

Published: 2013

Journal Articles

A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results

Craig Reeder, MD, Amylou Constance Dueck, PhD, Katherine Gano, Craig Nichols, Angela Toro, NP, Daniel Johnson, Patrick B. Johnston, Thomas M. Habermann, Jose F Leis, MD, PhD, Grzegorz S. Nowakowski, MD, Joseph Mikhael, MD, Joseph Colgan, Luis F. Porrata, MD, James L Slack, MD, Stephen M Ansell, Thomas E Witzig

Blood (2013) 122 (21): 4350.

https://doi.org/10.1182/blood.V122.21.4350.4350

Published: 2013

Journal Articles

Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona

Blood (2013) 122 (21): 2835.

https://doi.org/10.1182/blood.V122.21.2835.2835

Published: 2013

Journal Articles

Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant

Kristen Beebe, PA-C, Jane Olsen, NP, Yu-hui Chang, PhD, Mary Burkhart, NP, Lori DeCook, PA-C, Susan Gerber, PA-C, Kimberley Settineri, PA-C, Jane Palmer, NP, Joanne Schlesinger, NP, Roberta Adams, MD, Veena Fauble, MD, Nandita Khera, MD, MPH, Jared Klein, MD, Jose Leis, MD, PhD, Pierre Noel, MD, Meagan Higgins, NP, Craig Reeder, MD, James L Slack, MD, Lisa Sproat, MD, MSW

Blood (2013) 122 (21): 4616.

https://doi.org/10.1182/blood.V122.21.4616.4616

Published: 2013

Journal Articles

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Pier Luigi Zinzani, MD, Julie M Vose, MD, MBA, Myron S. Czuczman, MD, Craig Reeder, MD, Corinne Haioun, MD, Jonathan Polikoff, MD, Herve Tilly, Dennis Pietronigro, Annette Ervin-Haynes, Ju Li, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2738.

https://doi.org/10.1182/blood.V120.21.2738.2738

Published: 2012

Journal Articles

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Craig Reeder, MD, Stephen M Ansell, M.D., Ph.D., Katherine Gano, Amylou C. Dueck, PhD, Christopher Conley, MD, Grzegorz S. Nowakowski, Kelly Curtis, MD, John Camoriano, MD, Jose Leis, MD, PhD, James L Slack, MD, Riccardo Valdez, MD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Keith Stewart, MD, Thomas E. Witzig, MD

Blood (2012) 120 (21): 2741.

https://doi.org/10.1182/blood.V120.21.2741.2741

Published: 2012

Journal Articles

Impact of Vitamin D Level After Allogeneic Hematopoietic Stem Cell Transplant

Lisa Sproat, MD, MSW, Jane Olsen, NP, Kristen Beebe, PA-C, Rochelle Chiffelle, DNP, Susan Gerber, PA-C, Brooke Loewen, PA-C, Jane Palmer, NP, Angela Toro, NP, Roberta Adams, MD, Veena Devi Salem Fauble, MD, Nandita Khera, MD, Jose Leis, MD, PhD, Craig Reeder, MD, James L Slack, MD, Pierre Noel, MD

Blood (2012) 120 (21): 1954.

https://doi.org/10.1182/blood.V120.21.1954.1954

Published: 2012

Journal Articles

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients

Blood (2012) 120 (21): 201.

https://doi.org/10.1182/blood.V120.21.201.201

Published: 2012

Journal Articles

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Grzegorz S. Nowakowski, MD, Betsy R. LaPlant, Craig Reeder, MD, James M. Foran, MD, FRCPC, Luis F. Porrata, MD, William R Macon, MD, Patrick B. Johnston, MD, PhD, Candido E. Rivera, MD, Thomas M Habermann, MD, David J. Inwards, MD, Ivana N. Micallef, MD, Garth D Nelson, Stephen M. Ansell, M.D., Ph.D., Thomas E. Witzig, MD

Blood (2012) 120 (21): 689.

https://doi.org/10.1182/blood.V120.21.689.689

Published: 2012

Journal Articles

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

Blood (2012) 119 (23): 5397–5404.

https://doi.org/10.1182/blood-2012-02-413161

Published: 2012

Journal Articles

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Blood (2011) 118 (11): 2970–2975.

https://doi.org/10.1182/blood-2011-04-348896

Published: 2011

Journal Articles

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Blood (2008) 112 (11): 91.

https://doi.org/10.1182/blood.V112.11.91.91

Published: 2008

NARROW

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Concomitant Myeloproliferative Disorders (MPD) and Amyloidosis

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma

Smoldering multiple myeloma requiring treatment: time for a new definition?

The AKT Inhibitor MK2206 In Combination With Rituximab and Bendamustine Is Tolerable and Active In Relapsed Or Refractory Chronic Lymphocytic Leukemia: Results From a Phase 1 Study (NCCTG N1087 Alliance)

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

A Phase I/II Trial Of Pomalidomide, Bortezomib and Dexamethasone In Patients With Relpased Or Refractory Multiple Myeloma

Interference Of The Tumor Supportive Effects Of BCL2 and MCL1 Sensitize Malignant Plasma Cells To The Lethal Effects Of Lenalidomide and Dexamethasone Regimen: An Important Clinical Path For BCL2 Targeting Drugs

A Phase 2 Study Of Lenalidomide, Rituximab, Cyclophosphamide and Dexamethasone (LR-CD) For Untreated Low Grade Non-Hodgkin Lymphoma Requiring Therapy: Waldenström’s Macroglobulinemia Cohort Results

A Phase I/II Combination Of RAD001 (Everolimus) and Lenalidomide For Relapsed Lymphoid Malignancy: Phase I Results

Reduced Toxicity Conditioning With Fludarabine, BCNU, Melphalan and Anti-Thymocyte Globulin Followed By Allogeneic Stem Cell Transplant For Patients With Primary and Post ET/PV Myelofibrosis: Single Center Experience At Mayo Clinic Arizona

Impact Of Vitamin D Level Pre and Post Allogeneic Hematopoietic Stem Cell Transplant

Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.

Impact of Vitamin D Level After Allogeneic Hematopoietic Stem Cell Transplant

Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma: Long Term Follow up and Factors Predicing Outcome in 345 Patients

Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Phase II Trial of Lenalidomide (Revlimid ™ ) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only